418 related articles for article (PubMed ID: 23994105)
1. Defective expression of Protein 4.1N is correlated to tumor progression, aggressive behaviors and chemotherapy resistance in epithelial ovarian cancer.
Xi C; Ren C; Hu A; Lin J; Yao Q; Wang Y; Gao Z; An X; Liu C
Gynecol Oncol; 2013 Dec; 131(3):764-71. PubMed ID: 23994105
[TBL] [Abstract][Full Text] [Related]
2. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
3. Upregulation of Abelson interactor protein 1 predicts tumor progression and poor outcome in epithelial ovarian cancer.
Zhang J; Tang L; Chen Y; Duan Z; Xiao L; Li W; Liu X; Shen L
Hum Pathol; 2015 Sep; 46(9):1331-40. PubMed ID: 26193797
[TBL] [Abstract][Full Text] [Related]
4. 4.1N suppresses hypoxia-induced epithelial-mesenchymal transition in epithelial ovarian cancer cells.
Zhang L; Hu A; Li M; Zhang H; Ren C; An X; Liu C
Mol Med Rep; 2016 Jan; 13(1):837-44. PubMed ID: 26648170
[TBL] [Abstract][Full Text] [Related]
5. Cyclin A correlates with YB1, progression and resistance to chemotherapy in human epithelial ovarian cancer.
Cybulski M; Jarosz B; Nowakowski A; Jeleniewicz W; Kutarska E; Bednarek W; Stepulak A
Anticancer Res; 2015 Mar; 35(3):1715-21. PubMed ID: 25750333
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of trophoblast cell surface antigen 2 as an independent marker for a poor prognosis and as a potential therapeutic target in epithelial ovarian carcinoma.
Xu N; Zhang Z; Zhu J; Xu L; Li Y; Duan L; Mao Y; Li H
Int J Exp Pathol; 2016 Apr; 97(2):150-8. PubMed ID: 27127000
[TBL] [Abstract][Full Text] [Related]
7. Low MAD2 expression levels associate with reduced progression-free survival in patients with high-grade serous epithelial ovarian cancer.
Furlong F; Fitzpatrick P; O'Toole S; Phelan S; McGrogan B; Maguire A; O'Grady A; Gallagher M; Prencipe M; McGoldrick A; McGettigan P; Brennan D; Sheils O; Martin C; W Kay E; O'Leary J; McCann A
J Pathol; 2012 Apr; 226(5):746-55. PubMed ID: 22069160
[TBL] [Abstract][Full Text] [Related]
8. Loss of 4.1N in epithelial ovarian cancer results in EMT and matrix-detached cell death resistance.
Wang D; Zhang L; Hu A; Wang Y; Liu Y; Yang J; Du N; An X; Wu C; Liu C
Protein Cell; 2021 Feb; 12(2):107-127. PubMed ID: 32448967
[TBL] [Abstract][Full Text] [Related]
9. Clinical relevance of CD44 surface expression in advanced stage serous epithelial ovarian cancer: a prospective study.
Elzarkaa AA; Sabaa BE; Abdelkhalik D; Mansour H; Melis M; Shaalan W; Farouk M; Malik E; Soliman AA
J Cancer Res Clin Oncol; 2016 May; 142(5):949-58. PubMed ID: 26762850
[TBL] [Abstract][Full Text] [Related]
10. High GOLPH3 expression is associated with a more aggressive behavior of epithelial ovarian carcinoma.
Ma Y; Ren Y; Zhang X; Lin L; Liu Y; Rong F; Wen W; Li F
Virchows Arch; 2014 Apr; 464(4):443-52. PubMed ID: 24458516
[TBL] [Abstract][Full Text] [Related]
11. HPIP expression predicts chemoresistance and poor clinical outcomes in patients with epithelial ovarian cancer.
Wang Y; Li M; Meng F; Lou G
Hum Pathol; 2017 Feb; 60():114-120. PubMed ID: 27818289
[TBL] [Abstract][Full Text] [Related]
12. Altered expression of different GalNAc‑transferases is associated with disease progression and poor prognosis in women with high-grade serous ovarian cancer.
Sheta R; Bachvarova M; Plante M; Gregoire J; Renaud MC; Sebastianelli A; Popa I; Bachvarov D
Int J Oncol; 2017 Dec; 51(6):1887-1897. PubMed ID: 29039611
[TBL] [Abstract][Full Text] [Related]
13. Aberrant Beclin 1 expression is closely linked to carcinogenesis, differentiation, progression, and prognosis of ovarian epithelial carcinoma.
Zhao Y; Chen S; Gou WF; Xiao LJ; Takano Y; Zheng HC
Tumour Biol; 2014 Mar; 35(3):1955-64. PubMed ID: 24132590
[TBL] [Abstract][Full Text] [Related]
14. NEDD9 overexpression is associated with the progression of and an unfavorable prognosis in epithelial ovarian cancer.
Wang H; Mu X; Zhou S; Zhang J; Dai J; Tang L; Xiao L; Duan Z; Jia L; Chen S
Hum Pathol; 2014 Feb; 45(2):401-8. PubMed ID: 24439227
[TBL] [Abstract][Full Text] [Related]
15. Inflammation-regulating factors in ascites as predictive biomarkers of drug resistance and progression-free survival in serous epithelial ovarian cancers.
Lane D; Matte I; Garde-Granger P; Laplante C; Carignan A; Rancourt C; Piché A
BMC Cancer; 2015 Jul; 15():492. PubMed ID: 26122176
[TBL] [Abstract][Full Text] [Related]
16. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q
Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967
[No Abstract] [Full Text] [Related]
17. Epithelial protein lost in neoplasm-α (EPLIN-α) is a potential prognostic marker for the progression of epithelial ovarian cancer.
Liu R; Martin TA; Jordan NJ; Ruge F; Ye L; Jiang WG
Int J Oncol; 2016 Jun; 48(6):2488-96. PubMed ID: 27035883
[TBL] [Abstract][Full Text] [Related]
18. Loss of lamin A but not lamin C expression in epithelial ovarian cancer cells is associated with metastasis and poor prognosis.
Gong G; Chen P; Li L; Tan H; Zhou J; Zhou Y; Yang X; Wu X
Pathol Res Pract; 2015 Feb; 211(2):175-82. PubMed ID: 25499720
[TBL] [Abstract][Full Text] [Related]
19. Stomatin-like protein 2 is overexpressed in epithelial ovarian cancer and predicts poor patient survival.
Sun F; Ding W; He JH; Wang XJ; Ma ZB; Li YF
BMC Cancer; 2015 Oct; 15():746. PubMed ID: 26487491
[TBL] [Abstract][Full Text] [Related]
20. Significance of cell cycle regulatory proteins as malignant and prognostic biomarkers in ovarian epithelial tumors.
Lee YH; Heo JH; Kim TH; Kang H; Kim G; Kim J; Cho SH; An HJ
Int J Gynecol Pathol; 2011 May; 30(3):205-17. PubMed ID: 21464733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
